Company reports $74.1 million in Q1 total revenue, reflecting 61$44.4 million; XPHOZAH net product sales revenue of $23.4 million  Company ends Q1 with$214.0 million in cash, cash equivalents and investments Conference call scheduled for 4:30 PM Eastern Time WALTHAM, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-c ...